Leukotriene synthesis enzyme

Leukotriene synthesis enzymes are a group of cytosolic and membrane-bound enzymes that catalyze the conversion of arachidonic acid to leukotrienes, which are potent immune-modulating lipid mediators[1][8]. Key enzymes include cytosolic phospholipase A2α (which releases arachidonic acid from phospholipids), 5-lipoxygenase (5-LOX), 5-lipoxygenase-activating protein (FLAP), LTA4 hydrolase, and LTC4 synthase[1][6]. These enzymes are primarily expressed in myeloid and other immunocompetent cells, assemble at the nuclear or perinuclear membranes upon cell activation, and jointly produce the leukotrienes LTB4 (a chemoattractant for neutrophils), LTC4, LTD4, and LTE4 (cysteinyl leukotrienes involved in bronchoconstriction and inflammatory responses)[1][6]. Pharmacological inhibition of one or more of these enzymes is established in asthma and allergy therapy and is under investigation for other chronic inflammatory and neoplastic diseases[2][8]. However, "Leukotriene synthesis enzymes" is not a single standardized target, but a descriptive group encompassing several defined molecular entities (such as 5-lipoxygenase, LTA4 hydrolase, and LTC4 synthase); therefore, the term is too broad and not strictly correct as a canonical single-target name[1][8].

Other names

Leukotriene biosynthetic enzymeLeukotriene-synthesizing enzymeEnzymes in leukotriene biosynthesis

Enzyme inhibition (block leukotriene biosynthesis to reduce inflammatory signaling)